Enlightenment Research’s Atossa Therapeutics ATOS Stock Holding History

Enlightenment Research’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,873	Closed	-$462K	–	138
2021 Q2	$462K	Buy	+4,873	New	+$258K	0.59%	49

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Enlightenment Research's ATOS Position: Q3 2021 in Review

Enlightenment Research sold out of Atossa Therapeutics (ATOS) in Q3 2021, closing a stake of 4,873 shares — an estimated $462K sold.

Enlightenment Research first reported a position in ATOS in Q2 2021 and held it in 1 quarter. The position peaked at $462K in Q2 2021. 93 funds tracked by Wall St. Rank hold ATOS as of Q3 2021.

Enlightenment Research reported no remaining Atossa Therapeutics position as of Q3 2021 after selling out during the quarter.
Enlightenment Research sold 4,873 Atossa Therapeutics shares in Q3 2021, an estimated $462K.
Enlightenment Research first reported a position in Atossa Therapeutics in Q2 2021 and held it in 1 quarter.
Enlightenment Research's Atossa Therapeutics position peaked at $462K in Q2 2021.
93 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2021.

Based on Enlightenment Research's 13F filing for Q3 2021, filed 15 Nov 2021.